ATE339966T1 - Cd154-blockadetherapie der pankreasinselzelltransplantation bei primaten - Google Patents

Cd154-blockadetherapie der pankreasinselzelltransplantation bei primaten

Info

Publication number
ATE339966T1
ATE339966T1 AT98930436T AT98930436T ATE339966T1 AT E339966 T1 ATE339966 T1 AT E339966T1 AT 98930436 T AT98930436 T AT 98930436T AT 98930436 T AT98930436 T AT 98930436T AT E339966 T1 ATE339966 T1 AT E339966T1
Authority
AT
Austria
Prior art keywords
graft
compositions
primates
pancreas
cell transplantation
Prior art date
Application number
AT98930436T
Other languages
English (en)
Inventor
Norma S Kenyon
Camillo Ricordi
David W Thomas
Linda Burkly
Original Assignee
Biogen Idec Inc
Univ Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc, Univ Miami filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of ATE339966T1 publication Critical patent/ATE339966T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • External Artificial Organs (AREA)
  • Steroid Compounds (AREA)
AT98930436T 1997-06-20 1998-06-19 Cd154-blockadetherapie der pankreasinselzelltransplantation bei primaten ATE339966T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5026797P 1997-06-20 1997-06-20
US7726598P 1998-03-09 1998-03-09

Publications (1)

Publication Number Publication Date
ATE339966T1 true ATE339966T1 (de) 2006-10-15

Family

ID=26728084

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98930436T ATE339966T1 (de) 1997-06-20 1998-06-19 Cd154-blockadetherapie der pankreasinselzelltransplantation bei primaten

Country Status (21)

Country Link
US (2) US20030072754A1 (de)
EP (1) EP1051191B1 (de)
JP (1) JP2002506446A (de)
KR (1) KR100634847B1 (de)
CN (2) CN1195546C (de)
AT (1) ATE339966T1 (de)
AU (1) AU730763B2 (de)
BG (1) BG64976B1 (de)
BR (1) BR9810620A (de)
CA (1) CA2294154A1 (de)
DE (1) DE69835965T2 (de)
EA (1) EA002550B1 (de)
EE (1) EE9900588A (de)
HU (1) HUP0003160A3 (de)
IL (1) IL133303A0 (de)
IS (1) IS5273A (de)
NO (1) NO996275L (de)
NZ (1) NZ502052A (de)
SK (1) SK180299A3 (de)
TR (1) TR199903142T2 (de)
WO (1) WO1998058669A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999045958A1 (en) * 1998-03-09 1999-09-16 Biogen, Inc. Cd154 blockade therapy for modulation of immune responses to implanted devices
AU2001251612A1 (en) 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
CA2410786A1 (en) * 2000-06-02 2001-12-13 Regents Of The University Of Minnesota Immunotherapeutic method to prevent islet cell rejection
KR20030007899A (ko) * 2000-06-09 2003-01-23 브리스톨-마이어스스퀴브컴파니 림프구성 신호의 차단 및 ｌｆａ-1 매개 접착의 차단을통한 세포-매개 면역 반응의 조절 방법
KR20120090094A (ko) * 2003-06-13 2012-08-16 바이오겐 아이덱 엠에이 인코포레이티드 아글리코실 항-ｃｄ154(ｃｄ40 리간드) 항체 및 이의 용도
EP2399936A3 (de) 2004-07-26 2012-02-22 Biogen Idec MA Inc. Anti-CD154-Antikörper
EP1814980B1 (de) * 2004-11-22 2015-03-25 Ramot at Tel-Aviv University Ltd. Populationen expandierter und rückdifferenzierter adulter beta-inselzellen mit der fähigkeit zur produktion von insulin sowie verfahren zur erzeugung davon
WO2007047539A2 (en) * 2005-10-14 2007-04-26 Medtronic, Inc. Localized delivery to the lymphatic system
US8636995B2 (en) 2006-08-31 2014-01-28 Cardiac Pacemakers, Inc. Methods and devices to regulate stem cell homing
US8372399B2 (en) 2006-08-31 2013-02-12 Cardiac Pacemakers, Inc. Bispecific antibodies and agents to enhance stem cell homing
CN102388063B (zh) 2009-02-10 2016-04-20 纽约哥伦比亚大学理事会 5c8Mab和调节性CD8+T细胞直接诱导在建立持久和特异性移植耐受中的用途
WO2011146395A2 (en) 2010-05-17 2011-11-24 The Board Of Trustees Of The Leland Stanford Junior University Prevention of immunological rejection of transplanted stem cells by leukocyte costimulatory molecule blockade
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US10147463B2 (en) 2014-12-10 2018-12-04 Nxp Usa, Inc. Video processing unit and method of buffering a source video stream
US9512229B2 (en) 2015-03-03 2016-12-06 Kymab Limited Synergistic combinations of OX40L antibodies for the treatment of GVHD
KR101810778B1 (ko) * 2015-06-23 2017-12-20 서울대학교산학협력단 Cd154 결합 폴리펩타이드 및 그 용도
US10986309B2 (en) 2015-06-30 2021-04-20 Nxp Usa, Inc. Video buffering and frame rate doubling device and method
TWI640536B (zh) 2016-06-20 2018-11-11 克馬伯有限公司 抗體
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5227298A (en) * 1990-08-17 1993-07-13 The Trustees Of Columbia University In The City Of New York Method for microencapuslation of cells or tissue
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
PT892643E (pt) * 1996-03-20 2002-09-30 Univ Emory Metodos para inibir uma resposta imunitaria bloqueando os circuitos de gp39/cd40 e ctla4/cd28/b7 e composicoes utilizaveis para o efeito

Also Published As

Publication number Publication date
DE69835965D1 (de) 2006-11-02
TR199903142T2 (xx) 2000-09-21
JP2002506446A (ja) 2002-02-26
CN1195546C (zh) 2005-04-06
SK180299A3 (en) 2000-06-12
HUP0003160A2 (hu) 2001-01-29
US20030072754A1 (en) 2003-04-17
WO1998058669A3 (en) 1999-04-29
IS5273A (is) 1999-11-26
BR9810620A (pt) 2000-10-03
US20070292440A1 (en) 2007-12-20
EP1051191B1 (de) 2006-09-20
EP1051191A2 (de) 2000-11-15
HUP0003160A3 (en) 2002-09-30
WO1998058669A2 (en) 1998-12-30
AU7983098A (en) 1999-01-04
DE69835965T2 (de) 2007-06-14
NO996275L (no) 2000-02-21
CN1651919A (zh) 2005-08-10
HK1033548A1 (en) 2001-09-07
EE9900588A (et) 2000-08-15
IL133303A0 (en) 2001-04-30
EA200000058A1 (ru) 2000-08-28
AU730763B2 (en) 2001-03-15
BG104091A (en) 2000-10-31
NO996275D0 (no) 1999-12-17
EA002550B1 (ru) 2002-06-27
CN1261286A (zh) 2000-07-26
NZ502052A (en) 2001-01-26
BG64976B1 (bg) 2006-11-30
KR20010013965A (ko) 2001-02-26
CA2294154A1 (en) 1998-12-30
KR100634847B1 (ko) 2006-10-17

Similar Documents

Publication Publication Date Title
ATE339966T1 (de) Cd154-blockadetherapie der pankreasinselzelltransplantation bei primaten
ATE71298T1 (de) Immunoregulation.
DK1066052T3 (da) Mesenchymstamceller til forebyggelse og behandling af immunreaktioner ved transplantationer
ATE314393T1 (de) Verzögerte freigabe von insulinotropin (glp-1)
WO1998009618A3 (en) Graft survival prolongation with porphyrins
DK0735890T3 (da) Blandinger af 2',3'-dideoxyinosin og hydroxycarbamid til hæmning af retroviral spredning
AU5392001A (en) Taci as an anti-tumor agent
IL158384A0 (en) Treatment or prophylaxis of insulin producing cell graft rejection
Henquin et al. Dibutyryl cyclic AMP triggers Ca2+ influx and Ca2+-dependent electrical activity in pancreatic B cells
PT1451302E (pt) Folhas reconstituídas in vitro de epitélio corneal humano e método de produção das mesmas
WO2006012404A3 (en) Novel cell populations and uses thereof
HARRIS et al. Immunodeficiency in chronic uremia: preliminary evidence for thymosin deficiency
MXPA04010855A (es) Uso del xenon para el control de deficits neurologicos asociados con derivados cardiopulmonar.
WO1993006852A3 (en) Methods of improving allograft or xenograft tolerance by administration of an lfa-3 or cd2 binding protein
DK0673422T3 (da) Celler, der er modificeret med hensyn til katabolismen af betain, fremstilling og anvendelser, navnlig til produktion af metabolitter eller enzymer
GR900100535A (en) Substituted 2-imidazolines and preparation and use thereof
GR930300003T1 (en) Inhibitor of proliferation of endothelial cells.
EP1754490A3 (de) CD154-Blockadetherapie der Pankreasinselzellentransplantation bei Primaten
NZ237739A (en) Pharmaceutical composition of a complement inhibitor and an immunosuppressant with cyclosporin a-like activity, and its use
Egel et al. Renal failure in heart transplant patients receiving cyclosporine.
WO2001090316A3 (en) Human circulating dendritic cell compositions and methods
SE9003181D0 (sv) Use of heparin fraction
PL356240A1 (en) Use of treosulfan for patient conditioning before bone marrow or blood stem cell transplantation
EP0886528A4 (de) Verwendung Von Coxiella Bakterien zur Behandlung von Autoimmunkrankheiten
DE69231583D1 (de) Zusammensetzung zur Behandlung des Insulinmangels bei Säugetieren, die Amylin und Insulin enthält.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1051191

Country of ref document: EP

REN Ceased due to non-payment of the annual fee